https://www.selleckchem.com/pr....oducts/tat-beclin-1-
012). Pirfenidone treatment significantly decreased the Kyn/Trp ratio (0.030 ± 0.011 baseline vs 0.025 ± 0.010 post-treatment, = 0.048) whilst nintedanib treatment significantly increased blood GSH (486 ± 70 μmol/L vs 723 ± 194 μmol/L, = 0.006) and reduced ADMA concentrations (0.501 ± 0.094 vs. 0.468 ± 0.071 μmol/L, = 0.024). pirfenidone and nintedanib exert beneficial effects on specific markers of oxidative stress and inflammation in IPF patients. pirfenidone and nintedanib exert beneficial effects on specific markers o
Like
Comment
Share
